Leavell Investment Management Inc. Buys 5,325 Shares of Amgen Inc. (NASDAQ:AMGN)

Leavell Investment Management Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 42.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,756 shares of the medical research company's stock after purchasing an additional 5,325 shares during the quarter. Leavell Investment Management Inc.'s holdings in Amgen were worth $5,721,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AIA Group Ltd bought a new stake in shares of Amgen in the first quarter valued at about $612,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Amgen in the first quarter valued at about $2,957,000. Montag A & Associates Inc. lifted its stake in shares of Amgen by 84.8% in the first quarter. Montag A & Associates Inc. now owns 5,775 shares of the medical research company's stock valued at $1,642,000 after buying an additional 2,650 shares during the period. Atomi Financial Group Inc. lifted its stake in shares of Amgen by 115.1% in the first quarter. Atomi Financial Group Inc. now owns 3,736 shares of the medical research company's stock valued at $1,062,000 after buying an additional 1,999 shares during the period. Finally, Chilton Capital Management LLC lifted its stake in shares of Amgen by 5.9% in the first quarter. Chilton Capital Management LLC now owns 67,615 shares of the medical research company's stock valued at $19,224,000 after buying an additional 3,773 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. StockNews.com upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. Jefferies Financial Group restated a "buy" rating and set a $380.00 price target (up previously from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Truist Financial cut shares of Amgen from a "buy" rating to a "hold" rating and raised their price target for the stock from $320.00 to $333.00 in a research note on Monday, October 14th. Finally, Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Amgen currently has an average rating of "Moderate Buy" and an average target price of $333.50.

Amgen Trading Up 1.0 %

AMGN traded up $3.37 during trading on Friday, reaching $325.28. 1,978,146 shares of the company's stock were exchanged, compared to its average volume of 1,763,584. The company's fifty day moving average price is $323.61 and its 200-day moving average price is $317.08. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The firm has a market capitalization of $174.85 billion, a PE ratio of 41.65, a P/E/G ratio of 2.87 and a beta of 0.60.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analysts' expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period last year, the firm posted $4.96 earnings per share. As a group, equities analysts forecast that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.77%. Amgen's dividend payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.